Biotech Drug Delivery Systems - Key Company Intelligence & Market Outlook to 2012

Questions: Discounts, Updates etc.

Pages: 92

Price (Single): £1,299

Price (Departmental): £2,999

Price (Company): £4,999

Publication Date: 2007-02-19

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *


The two major problems for biotech drugs are their mode of delivery and relative instability. The majority of delivery methods for biological drugs involve injection, which is not necessarily ideal for most indications. As the biotech sector starts to heat up, the industry has started to look for new ways of delivering these highly successful drugs.

Two main themes that run through this report: patent loss for leading biotech drugs and the use of technology to enable newer drugs to be more effective. Central to both of these matters is the perception that new drugs rely on old delivery technologies to get past the regulatory authorities, whereas old drugs look to new techniques to survive. This report will examine and challenge that approach; visiongain suggests that pharmaceutical companies should look to new drug delivery systems as they develop new drugs, in order to make the most out of these technologies.  The report provides:

- Revenue forecasts for the biological drug delivery market
- Drivers and restraints of the market are identified and discussed
- An analysis of strengths, weaknesses opportunities and threats (SWOT) for the biological drug delivery market
- Future targets for drug delivery technology
- Summaries and analysis of the leading drug delivery companies and their pipelines
- Special focus on oral drug delivery and injection technologies
- An assessment of potential advances, including the challenge of RNA delivery

In stark contrast to the pharmaceutical market as a whole, which is exhibiting single digit growth, the biotech market is still growing significantly with constantly innovative products. The proven methods, such as intravenous infusion and intra-muscular/subcutaneous injection, have remained the standard mode of administration, whereas the novelty has come from new improved protein therapeutics. This situation may be set to change, however, as key products lose patent protection and the market for some biotech drugs becomes more congested.

The report answers key questions such as:
- Which drug delivery companies are likely to be at the forefront of Biotech launches?
- What will be the revenue impact of altering the drug delivery method of patented drugs?
- What will be the revenue in 2012 for biotech drugs using novel drug delivery methods?
- How will the regulatory rulings involving Biosimilar products effect innovation?
- Understand the effect of nanotechnology on the drug delivery methods of biotech drugs

This report includes visiongain's predictions of the Top 10 drugs most likely to be targeted for Biogenerics and the impact on revenue to their current manufacturers.

Table of Contents

  • Chapter 1.
  • Executive Summary

  • Introduction
  • Chapter 2.

  • Chapter 3.
  • World Market for Biological Drug Delivery

  • Chapter 4.

  • Blurs Drug Delivery Lines

  • Chapter 5. Transdermal Delivery Technology

  • Chapter 6. Pipeline: Oral Delivery of Biotech Drugs

  • Chapter 7. The Challenge of RNA Delivery

  • Chapter 8.
  • Conclusion: The Market Shows Huge Potential But Many Hurdles Still Remain

  • List of Tables
  • Table 2.1, Top Ten Biotech Drugs
  • Table 2.2, Pegylated Interferon Drugs 2006
  • Table 2.3, Amino Acid Changes for Human Insulin Analogues
  • Table 3.1, Revenues for Vaccines
  • Table 3.2, Revenue Forecast For Biotech Drugs Using Novel Drug Delivery Technology 2012
  • Table 4.1, SWOT Analysis for the Biological Drug Delivery Market, 2006
  • Table 4.2, Possible Biogeneric Targets for Drug Delivery Companies
  • Table 4.3, Biotech Drugs Losing Patent Protection 2007-2012
  • Table 5.1, Doses for Leading Monoclonal Antibodies
  • Table 5.2, Needle-free Injection Devices Developed by Equidyne Systems
  • Table 6.1, Biotech Products and Pipeline Drugs Using Nektar's Technology Platforms, 2006
  • Table 6.2, Partnership Deals in Emisphere's Pipeline, 2006
  • Table 6.3, Proprietary Drug Candidates from Emisphere, 2006
  • Table 6.4, Drugs in the Pipeline for Merrion Pharmaceuticals,2006
  • Table 6.5, Nastech's Biotech Pipeline 2006
  • Table 7.1, Preclinical/Clinical Development Programs in the Santaris Pipeline, 2006
  • Table 7.2, Preclinical Development Programs in the Nucleonics Pipeline, 2006

  • List of Figures
  • Figure 2.1, World Revenue Forecast for the World Biotech Market
  • Figure 3.1, Global Revenues for Pegylated and non-Pegylated Interferons
  • Figure 3.2, Historical Sales Figures for Neupogen/Neulasta, 1996-2006
  • Figure 3.3, Revenues ($m) for Insulin and Oral Anti-diabetics
  • Figure 3.4, Market Share by Brand Name for Somatropin Products
  • Figure 3.5, Geographical Breakdown of the World Vaccine Market
  • Figure 3.6, Technology Classes in the Biotech Pipeline
  • Figure 3.7, World Revenue ($m) Forecast for Monoclonal Antibody Drugs
  • Figure 3.8, Revenues ($m) for Off-Patent Biotech Drugs 2012
  • Figure 3.9, Revenue Forecast For Biotech Drugs Using Novel Drug Delivery Technology 2012
  • Figure 3.10 Forecast Growth Rates For Biotech Drugs Using Novel Drug Delivery Technology 2012
  • Figure 4.1, Historical Sales Revenues for Pegylated Therapeutic Proteins, 2004-2006
  • Figure 4.2, Different Approaches to Biological Drug Delivery
  • Figure 8.1, Stages of Development for RNAi based Therapies

    • Other users found this report page using the following search terms: drug delivery innovator drug insulin pegylated questions formulations revenue biological biotech delivery

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.